Lumakras

Mirati was seeking approval for the drug for treating patients with advanced lung cancer who have stopped responding to other…

The medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13 per cent of non-small cell…

The findings are the first indication of how well Lumakras works in combination with drugs that help the immune system attack…